r Progression of hypoxic pulmonary hypertension is thought to be due, in part, to suppression of voltage-gated potassium channels (K v ) in pulmonary arterial smooth muscle by hypoxia, although the precise molecular mechanisms have been unclear.
Introduction
Hypoxia without hypercapnia induces pulmonary vasoconstriction, and thus assists ventilation-perfusion matching in the lung (von Euler & Liljestrand, 1946) . However, hypoxia may trigger pulmonary hypertension when it is widespread, for example during ascent to altitude (Bartsch et al. 2005) or due to disorders such as cystic fibrosis (Lahm et al. 2014) . While current therapies have been shown to prolong survival, pulmonary hypertension remains a life-threatening disorder (Lahm et al. 2014 ) and the precise molecular mechanisms underlying it remain unclear. Therefore, greater understanding is critical to the development of effective therapies.
Initially, hypoxic pulmonary vasoconstriction (HPV) is driven by calcium release via ryanodine receptors from the sarcoplasmic reticulum of pulmonary arterial smooth muscle cells (Dipp et al. 2001) , but is also associated with concomitant inhibition of voltage-gated potassium channels (K v ) (Post et al. 1992; Yuan et al. 1993; Archer et al. 2004) . The role of K v channel inhibition in acute HPV remains open to debate (Wilson et al. 2002; Wang et al. 2004; Evans et al. 2005; Lu et al. 2008) , but it has been proposed that loss of K v function contributes to smooth muscle proliferation and thus to the progression of pulmonary hypertension (Sweeney & Yuan, 2000; Moudgil et al. 2006) by promoting cell survival (Ekhterae et al. 2001 (Ekhterae et al. , 2003 .
K v current suppression during hypoxia (Post et al. 1992; Yuan et al. 1993; Firth et al. 2008) occurs as a consequence of inhibition of mitochondrial oxidative phosphorylation (Firth et al. 2008 (Firth et al. , 2009 ). However, the nature of the signalling pathway that couples mitochondrial function to K v channels has been unclear. In this respect, little attention has been paid to the role of the AMP-activated protein kinase (AMPK), although we have previously proposed that it couples inhibition of mitochondrial metabolism by hypoxia to acute HPV (Evans et al. 2005; Evans, 2006) and may also contribute to the progression of pulmonary hypertension (Evans et al. 2005; Evans, 2006; Ibe et al. 2013; Goncharov et al. 2014) . AMPK, an energy sensor that acts to maintain cellular energy homeostasis, exists as heterotrimers comprising catalytic α subunits and regulatory β and γ subunits (Hardie, 2014a,b,c) . AMPK is coupled to mitochondrial metabolism through changes in the cellular AMP:ATP and ADP:ATP ratios. Binding of AMP to the γ subunit causes a 10-fold increase in AMPK activity by allosteric activation, but a further activation of up to 100-fold can be generated by binding of either AMP or ADP, which promotes phosphorylation and inhibits dephosphorylation of Thr172 on the α subunit; these effects are antagonised by ATP (Gowans et al. 2013; Ross et al. 2016) . Thr172 is primarily phosphorylated by the tumour suppressor kinase LKB1 (liver kinase B1), which appears to be constitutively active (Sakamoto et al. 2004 ), but which phosphorylates AMPK more rapidly when AMP is bound to the γ subunit. In an alternative Ca 2+ -dependent activation mechanism, the calmodulin-dependent protein kinase CaMKKβ can also phosphorylate Thr172 and hence activate AMPK in an AMP-independent manner (Hardie, 2014a,b,c) . The classical role of AMPK is to maintain energy homeostasis under conditions of metabolic stress, by activating catabolic processes that generate ATP and inhibiting non-essential anabolic processes that consume ATP. However, AMPK has also been shown to regulate a wide variety of ion channels and membrane transport proteins (Evans et al. 2009; Lang & Foller, 2014) , including K v 2.1 , KCa3.1 , and Kir 2.1 and K v 7.1 (Lang & Foller, 2014) .
Of the various known K v channel types, it has been established that both K v 2.1 and K v 1.5 contribute to voltage-gated potassium currents in pulmonary arterial myocytes (Smirnov et al. 2002; Archer et al. 2004; Firth et al. 2011; Olschewski et al. 2014) . Their relative contributions vary in a manner related to arterial diameter, with the greatest level of K v 1.5 expression (and contribution to K v currents) occurring in myocytes from near-resistance-sized arteries (Archer et al. 1998 Smirnov et al. 2002; Moral-Sanz et al. 2011) , the response of which to hypoxia is critical to acute increases in pulmonary arterial perfusion pressure. Moreover, selective down-regulation of K v 1.5 has been identified as a hallmark of pulmonary hypertension (Yuan et al. 1998; Michelakis et al. 2002; Bonnet et al. 2006; Remillard et al. 2007; Burg et al. 2010; Morales-Cano et al. 2014) . Consistent with this view, overexpression of K v 1.5 enhances apoptosis (Brevnova et al. 2004) , while adenoviral expression of a K v 1.5 transgene in vivo reduces pulmonary hypertension and restores HPV (Pozeg et al. 2003) .
We show here that AMPK selectively inhibits K v 1.5 in pulmonary arterial myocytes, and also phosphorylates and inhibits recombinant K v 1.5 channels expressed in HEK 293 cells.
Methods

Ethical approval
All experiments were performed under the United Kingdom Animals (Scientific Procedures) Act 1986. The animals used in this study were male Sprague Dawley rats that underwent no experimental procedures as recognised under UK Law. They were killed using a Schedule 1 method for collection of tissues only, which does not require formal ethical approval in the UK. Frozen canine tissue was left over from a previous project where surgical procedures and protocols were approved by the Cleveland Clinic Foundation Institutional Animal Care and Use Committee (Cleveland, OH, USA).
Smooth muscle cell isolation
Resistance pulmonary arteries (<200 μm inner diameter) from male Sprague Dawley rats (250-350 g) were dissected into a physiological bath solution of composition (in mM): NaCl 135, KCl 5, MgCl 2 1, CaCl 2 1, glucose 10, Hepes 10 (pH 7.4). For cell isolation, endothelium denuded arteries were transferred into a nominally calcium-free bath solution containing (in mg ml −1 ): 1 papain, 0.8 dithiothreitol and 0.7 BSA. The tissue was incubated in the latter solution for 10 min at 37°C and gently triturated using a fire polished glass pipette to get dispersed pulmonary arterial smooth muscle cells.
Electrophysiological recordings
Pulmonary arterial myocytes or HEK 293 cells that stably expressed K v 1.5 were transferred to a recording chamber and perfused at 1 ml min 
, where G max is the maximal conductance, V mid is the test potential for half-maximal conductance (G 0.5 ) and k represents the slope of the activation curve. Patch pipettes had resistances of 4-6 M . Series resistance was compensated for (60-80%) after achieving the whole-cell configuration. Signals were sampled at 10 kHz and low-pass filtered at 2 kHz. Voltage-clamp acquisition and analysis protocols were performed using an Axopatch 200A amplifier/Digidata 1200 interface controlled by Clampex 10.0 software (Molecular Devices, Sunnyvale, CA, USA). Off-line analysis was performed using Clampfit 10.0 (Molecular Devices). Data are expressed as current density (pA pF -1 ) or I/I zero , where I zero is the current magnitude recorded at the onset of a given experimental intervention.
Cell culture and transfection
HEK 293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) penicillin/streptomycin. Cells were transfected following the manufacturer's instructions with 12 μg of pcDNA3.1 encoding an HA-tagged human K v 1.5 (KCNA5) using Fugene 6 (Promega, Madison, WI, USA) and lysed 48 h later.
RT-PCR
Total RNA was isolated from frozen canine tissues and from frozen pelleted HEK 293 cells stably expressing K v 1.5, using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) as per the manufacturer's instructions. Reverse transcription PCRs (RT-PCRs) were carried out on 200 ng of total RNA using the One-Step RT-PCR Kit J Physiol 594.17 (ABM, Richmond, Canada) as recommended in the manual. Then, 20 μl of the 50 μl reaction was run on a 1% agarose gel and visualised using Safe-White (ABM) and a GelDoc equipped with Quantity One software (BioRad, Hercules, CA, USA). K v β primer sequences were as previously published and for the reference gene ReadyMade GAPDH primers (Integrated DNA Technologies, Coralville, IA, USA) were used with sequences as follows: GAPDH-For, ACCACAGTCCATGCCATCAC; GAPDH-Rev, TCCACCACCCTGTTGCTGTA. RT-PCR was repeated with 250 ng of template and 35 cycles of PCR after very faint bands were observed in the K v 1.5 stable cell line for K v β1 and K v β3. Canine ventricle was also repeated for comparison.
K v 1.5 phosphorylation assays
Phosphorylation assays were performed as described previously ) using AMPK purified from bacteria and phosphorylated with CAMKKβ (10 units ml −1 ) in the presence of 200 μM AMP for 30 min at 30°C.
Expression, purification and activation of bacterial AMPK
These were performed as described previously .
Isoform-specific AMPK activities
Isoform-specific AMPK activity was determined by immunoprecipitating tissue lysate with antibodies raised against α1 or α2 subunits bound to protein G-Sepharose beads and quantified using the AMARA peptide and [γ-32 P]ATP substrates (Cheung et al. 2000) .
Statistics
Data are expressed as means ± SEM or means ± SD, as indicated; n represents the number of cells tested from at least four different animals. Statistical analysis was performed using Student's t test for paired observations or one-way ANOVA followed by a Dunnett's post hoc test. Differences were considered statistically significant at P < 0.05.
Results
Inhibition of mitochondrial oxidative phosphorylation activates AMPK and reduces K v 1.5 current density in pulmonary arterial myocytes
Biguanide drugs such as phenformin inhibit complex I of the mitochondrial respiratory chain (El-Mir et al. 2000; Owen et al. 2000; Evans et al. 2005) and elicit consequent increases in the cellular AMP:ATP ratio and AMPK activation (Hawley et al. 2010) . Consistent with this, pre-incubation of second-and third-order pulmonary arteries with phenformin (4 h) increased AMPK-α1-associated activity from (mean ± S.D.) 0.025 ± 0.001 to 0.403 ± 0.012 nmol min −1 mg −1 protein and AMPK-α2-associated activity from 0.0096 ± 0.001 to 0.126 ± 0.006 nmol min −1 mg −1 protein (Fig. 1A , n = 3; 32 arteries, 8 rats). Furthermore, and in accordance with previously reported effects of mitochondrial inhibitors (Firth et al. 2008 ) and hypoxia , pre-incubation of acutely isolated pulmonary arterial myocytes with 1 mM phenformin (2-4 h) also caused pronounced reductions in K v current density, from 126 ± 17 pA pF -1 in time-matched controls to 55 ± 6 pA pF -1 at +40 mV ( Fig. 1Ca-b , n = 9-11, P < 0.001). Consistent with the effects of phenformin and previous investigations by others (Firth et al. 2008) , acute application of antimycin A (1 μM), a rapidly acting inhibitor of complex III, caused equivalent reductions in K v current density, from 131.3 ± 10.4 to 62.6 ± 11.1 pA pF -1 at +40 mV ( Fig. 1Da -b, n = 6, P < 0.001). Unless stated, in these and all subsequent experiments on pulmonary arterial myocytes, potassium currents were recorded in the presence of paxilline (1 μM) to block the large conductance voltage-and calcium-activated K + (BK Ca ) channel. Given that the contribution to native K v currents of K v 2.1 and K v 1.5 varies, in a manner related to both the size and the regional location within the lung of the arteries from which myocytes are derived (Smirnov et al. 2002) , we assessed the nature of the channels that underpin the K v current within the cells under study. Application of the K v 1.5 blocker diphenyl phosphine oxide-1 (DPO-1, 1 μM, Fig. 1B ) in the absence of paxilline caused almost total inhibition of the K v currents (96 ± 1% at +40 mV; n = 6, P < 0.0001), consistent with the view that K v 1.5 drives the majority of voltage-gated K + currents in myocytes of the near-resistance-sized pulmonary arteries studied here, which contribute most to the increase in pulmonary vascular resistance during hypoxia (Kato & Staub, 1966; Archer et al. 2004 ).
AMPK activation inhibits K v 1.5 currents in pulmonary arterial myocytes
We next assessed the effect on K v 1.5 current amplitude of extracellular application of three AMPK activators with distinct mechanisms of action, i.e. A769662, 5-aminoimidazole-4-carboxamide riboside (AICAR) and C13. Analysis of the time course for K v 1.5 inhibition at steady-state activation (100 ms at +40 mV) showed the time to onset of effect for A769662 (100 μM), AICAR (1 mM) and C13 (30 μM) to be around 2 min, with apparent maxima for inhibition achieved after 8-10 min (Fig. 2B) . After 10 min, K v 1.5 currents had declined ( Fig. 2A ) from 144 ± 12 to 101 ± 9 pA pF -1 in the presence of A769662 (n = 14), from 186 ± 23 to 136 ± 17 pA pF -1 in the presence of AICAR (n = 6) and from 164 ± 8 to 104 ± 10 pA pF -1 in the presence of C13 (n = 8). Note, however, that in 3 of 9 cells superfused with AICAR we observed no effect (excluded from analysis).
Surprisingly, we also observed inhibition of K v 1.5 currents upon application of the non-selective AMPK antagonist compound C (30 μM), from 164 ± 62 to 59 ± 24 pA pF -1 (n = 3; Fig. 2C ); this confounding effect precluded the use of this agent in further studies on myocytes. Previous studies have shown that compound C has little or no effect on resting pulmonary arterial tone, but inhibits acute HPV in a concentration-dependent manner (Robertson et al. 2008) , which must therefore be induced independently of the inhibition by hypoxia of K v 1.5 inhibition (Dipp et al. 2001) . It is worth noting that in a screen of 70 protein kinases, at least 10 were to +40 mV in 10 mV increments, holding potential −80 mV) from myocytes pre-incubated with 1 mM phenformin versus time-matched controls (C, green, n = 9-11), or before and after 5-8 min extracellular application of 1 μM antimycin A (D, n = 6). * P < 0.05, * * P < 0.01 and * * * P < 0.001.
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inhibited by compound C more potently than AMPK (Bain et al. 2007) . Thus, it is not a specific inhibitor of AMPK, a point reinforced by our findings that it markedly attenuates K v 1.5 function. This should be considered when interpreting outcomes of other cell-based assays that have employed compound C, not least with respect to myocyte proliferation and survival (Ibe et al. 2013 ).
-80 mV Results are expressed as mean ± SEM, n = 3-8.
Importantly, upon equilibration of pulmonary arterial myocytes with AICAR, A769662 and C13, reductions in current density were evident throughout the I-V range over which K v 1.5 currents were activated (Fig. 3A, B) . This was confirmed by the fact that A769662 was without effect on residual currents observed following pre-incubation of cells with DPO-1 even in the absence of paxilline (Fig. 3C) , current density measuring 10 ± 2 pA pF -1 in the presence of DPO-1 alone and 11 ± 3 pA pF -1 in the presence of DPO-1 and A769662 (n = 6).
Intracellular application of active AMPK heterotrimers inhibits K v 1.5 in pulmonary arterial myocytes Although A769662, AICAR and C13 activate AMPK by different mechanisms and are therefore unlikely to have the same off-target effects, we also analysed the effect on endogenous K v 1.5 channel function of bacterially expressed human AMPK heterotrimers (α2β2γ1 or α1β1γ1 complexes). These had been thiophosphorylated at Thr172 using CaMKKβ to yield active, recombinant AMPK that is also resistant to phosphatases . Intracellular dialysis of either of the active α2β2γ1 or α1β1γ1 heterotrimers (Fig. 4A) evoked K v 1.5 current inhibitions that were similar in magnitude (−33 ± 5% for α2β2γ1 and −36 ± 7% for α1β1γ1 at +40 mV; n = 5-7) to the reductions induced by pharmacological activation of AMPK. Importantly, current inhibition was not observed upon intracellular dialysis of an inactive AMPK heterotrimer [ Fig. 4B ; α2β2γ1 complex with D157A mutation in α2 ]. Based on the use both of pharmacological activation of endogenous AMPK and of exogenous recombinant AMPK, we can conclude that AMPK mediates, either directly or indirectly, inhibition of K v 1.5 currents in pulmonary arterial myocytes.
Hypoxia and mitochondrial inhibitors attenuate K v 1.5 currents and occlude further current inhibition by AMPK activation AMPK is intimately coupled to mitochondrial metabolism through changes in the AMP:ATP and ADP:ATP ratios (Gowans et al. 2013) , which is evident from the fact that AMPK activity was increased by hypoxia (Evans et al. 2005) and by the mitochondrial inhibitor phenformin (Fig. 1A) . To assess whether AMPK acted as a downstream mediator of K v 1.5 inhibition during hypoxia and inhibition of mitochondrial oxidative phosphorylation, we therefore carried out studies to determine if K v 1.5 inhibition by these stimuli was additive with respect to that induced by AMPK activators.
Superfusion of pulmonary arterial myocytes with a hypoxic solution (ß4% O 2 , > 10 min) markedly inhibited K v 1.5 currents, with a maximal reduction achieved after ß10 min (Fig. 5A , B, 150 ± 9 pA pF -1 during normoxia vs. 63 ± 6 pA pF -1 , n = 14-19, after 10-40 min of hypoxia; P < 0.001). Most importantly, continued hypoxia markedly attenuated the degree of K v 1.5 inhibition upon application of 100 μM A769662, which reduced current density from 53 ± 4 pA pF -1 during hypoxia alone to 45 ± 5 pA pF -1 (n = 6, P < 0.05; Figs 5B, C and 6A). As described previously, pre-incubation of acutely isolated myocytes with 1 mM phenformin (2 h) also caused pronounced reductions in K v current density, from 126 ± 17 to 55 ± 6 pA pF -1 at +40 mV (Fig. 1Ca-b , n = 9-11, P < 0.001). Moreover, and consistent with the effects of hypoxia, pre-incubation of cells with phenformin markedly attenuated the degree to which K v 1.5 currents were inhibited upon application of A769662, which reduced current density from 57 ± 12 pA pF -1 in the presence of phenformin alone to 49 ± 10 pA pF -1 (Figs 5Cb  and 6A ; n = 4, P = 0.09). In this respect antimycin A was equally effective, A769662 reducing K v 1.5 current density from 44 ± 4 pA pF -1 in the presence of antimycin A alone to 33 ± 4 pA pF -1 (Figs 5Cc and 6A ; n = 3, P < 0.05). Therefore, K v 1.5 inhibition by pharmacological AMPK activation is non-additive with respect to the action of either hypoxia or respiratory poisons. We can therefore conclude that in myocytes from near-resistance-sized pulmonary arteries, AMPK probably acts as the primary downstream mediator of K v 1.5 channel inhibition not only during hypoxia, but also in response to the inhibition of mitochondrial oxidative phosphorylation.
AMPK activators induce a leftward shift in the I-V relationship for K v 1.5 current activation that is occluded by hypoxia and mitochondrial inhibitors AMPK activation not only reduced K v 1.5 current density in pulmonary arterial myocytes throughout the I-V range over which K v 1.5 currents were activated, but also induced a significant 12-14 mV hyperpolarizing shift in the activation curve (Fig. 6B, C) analysed as G/G max and fitted to a single Boltzmann function. V mid measured: −17.9 ± 1.2 and −30.5 ± 4.5 mV in the absence and presence of AICAR, respectively; −17.4 ± 1.6 and −30.2 ± 3.5 mV in the absence and presence of A769662; −20.9 ± 2.6 and −39.7 ± 4.6 mV in the absence and presence of C13 (n = 5-7, P < 0.01). To allow for direct comparison of the maximal effect of each of these agents, we also expressed the leftward shift as the net change in V mid (Fig. 6B) ; V mid was −12.6 ± 4.8, −12.7 ± 2.4 and −18.7 ± 2.3 mV, respectively, for AICAR, A769662 and C13. As previously observed for current inhibition, the leftward shift in the I-V range for K v 1.5 activation that was induced by AMPK activation was non-additive with respect to the effect of hypoxia and prior inhibition of mitochondrial oxidative phosphorylation, V mid for A769662 measuring −4.5 ± 0.9 mV in the presence of hypoxia and −3.7 ± 0.6 mV in the presence of antimycin A.
To explore further the functional significance of a leftward shift in the I-V relationship we assessed the voltage-dependence of both K v 1.5 activation and inactivation in the absence and presence A769662, and 30 μM) ; measurements taken at end of pulse. C, representative current trances (a) and I-V relationships (b) for K v currents in the absence and presence of 1 μM DPO-1 and the effect of 100 μM A769662 in the continued presence of DPO-1. Results are expressed as mean ± SEM, n = 5-7. * P < 0.05, * * P < 0.01 and * * * P < 0.001.
thus determined the effect of AMPK activation on the window current, i.e. the proportion of current at a given potential that is never inactivated. Figure 7 clearly shows that AMPK activation by A769662 induced a leftward shift in K v 1.5 activation and inactivation curves and thus of the window current, lowering the threshold for activation while reducing the available non-inactivating current. To determine whether AMPK modulates K v 1.5 channel function directly, we examined the effects of AMPK activation on human K v 1.5 channels stably expressed in HEK 293 cells. Application of A769662 (100 μM) reduced K + currents carried by recombinant human K v 1.5 (Fig. 8Aa ) in a manner that was blocked by the non-selective AMPK inhibitor compound C (40 μM, Fig. 8B ). Moreover, intracellular dialysis of active AMPK α2β2γ1 or α1β1γ1 heterotrimers also reduced K v 1.5 currents, which remained unaffected in the presence of an inactive (D157A mutant) α2β2γ1 heterotrimer α1β1γ 1) . B, time course for reduction in K v current following intracellular dialysis of either active α2β2γ 1 (thiophosphorylated, 5 U ml −1 ), active α1β1γ 1 (thiophosphorylated, 5 U ml −1 ) or inactive α2β2γ 1 (D157A mutant) AMPK heterotrimer. Results are expressed as mean ± SEM, n = 5-7.
( Fig. 8Ab-C) . Like pulmonary arterial myocytes, therefore, currents carried by human K v 1.5 expressed in HEK 293 cells were similarly inhibited both by AMPK activators and by intracellular dialysis of recombinant active AMPK heterotrimers (Fig. 8D) . We also examined whether AMPK directly phosphorylates K v 1.5, using as substrate the human protein immunoprecipitated from these HEK 293 cells. . B, time course for reduction in K v current during extracellular superfusion with hypoxic solution and the effect of subsequent addition of 100 μM A769662; measurements taken at the end of a 100 ms step pulse to +40 mV. Ca, example records for voltage ramp and step protocol under normoxia (1), > 10 min of hypoxia (2), after 8 min of superfusion with hypoxia + 100 μM A769662 (3). Cb-c, as in a but representative current traces show the effect of 100 μM A769662 on myocytes pre-incubated with 1 mM phenformin (b) or after 20 min extracellular application of 1 μM antimycin A (c). * P < 0.05, * * P < 0.01 and * * * P < 0.001 vs. normoxia.
We first treated the immunoprecipitate with recombinant protein phosphatase (PP1γ) to remove endogenous phosphate groups, then phosphorylated with purified rat liver AMPK (a mixture of α1β1γ1 and α2β1γ1 isoforms) and [γ- -100 *** * ** ** * * ** ** *** *** *** *** *** Figure 6 . Comparison of the change in current density and voltage-conductance relationships induced by activated AMPK and AMPK activators in pulmonary arterial myocytes A, bar chart showing mean ± SEM change in current density at the end of each experimental intervention after 6-10 min of DMSO (1:1000), inactive α2β2γ 2, hypoxia (ß4% O 2 ), 5 U active α2β2γ 2, 5 U active α1β1γ 1, 1 mM AICAR, 100 μM A769662, 30 μM C13, 1 mM phenformin (2-4 h), 1 μM antimycin A, 100 μM A769662 in the presence of hypoxia (ß4% O 2 , > 10 min), phenformin and antimycin A (n = 3-16). B, similar to A but showing the net change in V mid of the voltage-conductance plots for 1 mM AICAR, 100 μM A769662, 30 μM C13, 1 μM antimycin A, 100 μM A769662 in the presence of 1 μM antimycin A and 100 μM A769662 in the presence of hypoxia (ß4% O 2 , > 10 min); n = 3-7. C, voltage-conductance plots showing effects of 1 mM AICAR (a), 100 μM A769662 (b), 30 μM C13 (c), 1 μM antimycin A (d), 100 μM A769662 in the presence of 1 μM antimycin A (e) and 100 μM A769662 in the presence of hypoxia (f, ß4% O 2 , > 10 min). Results are expressed as mean ± SEM, n = 3-7. * P < 0.05, * * P < 0.01 and * * * P < 0.001.
with serum albumin standards run on the same gel. We obtained estimates of 0.57 and 0.13 moles of phosphate per mole of protein in the presence and absence of AMP (data not shown). We repeated the experiment using recombinant human α1β1γ1 and α2β2γ1 complexes expressed in bacteria, and obtained stoichiometries of 0.7 and 1.6 moles of phosphate per mole of protein respectively (Fig. 8E , we did this only in the presence of AMP because, for reasons that remain unclear, the bacterially expressed complexes are much less AMP-dependent). While we have not yet determined the number and identity of the sites phosphorylated on K v 1.5, these results indicate that different AMPK complexes can catalyse a substantial AMP-activated phosphorylation of K v 1.5 in cell-free assays.
Discussion
The present investigation describes, for the first time, evidence that AMPK couples K v 1.5 channel function (defined by the K v 1.5 blocker DPO-1) to the inhibition by hypoxia of mitochondrial metabolism in pulmonary arterial myocytes. Consistent with this proposal, inhibition by phenformin or hypoxia of the mitochondrial electron transport chain (El-Mir et al. 2000; Owen et al. 2000 ) increases NAD(P)H autofluorescence (Evans et al. 2005) , activates AMPK and inhibits K v currents in pulmonary arterial myocytes. That AMPK activation may specifically regulate K v 1.5 in response to metabolic stresses such as hypoxia gained further support from our findings that AMPK activators that are structurally distinct and have different mechanisms of action, namely A769662, AICAR and C13, all markedly inhibited K v currents in pulmonary arterial myocytes. A769662, which primarily causes allosteric activation (Goransson et al. 2007; Scott et al. 2014) , binds in a site located between the α and β subunits of AMPK (Xiao et al. 2013) . AICAR (Corton et al. 1995) and C13 Gomez-Galeno et al. 2010) act similarly in the sense that they are both taken up into cells and converted to molecules (ZMP and C2, respectively) that bind to the γ subunit, mimicking the effects of AMP. However, C2 is a much more potent activator of AMPK than ZMP and, unlike the latter, does not affect other AMP-sensitive enzymes such as glycogen phosphorylase or fructose-1,6-bisphosphatase (Hunter et al. 2014) . Moreover, A769662 is selective for complexes containing the β1 subunit (Scott et al. 2008) , while C2 is selective for complexes containing the α1 subunit (Hunter et al. 2014) . These data suggest that K v 1.5 current inhibition in pulmonary arterial myocytes may be delivered in whole or in part by AMP-dependent activation of heterotrimers containing α1 and β1. Furthermore, inhibition of K v 1.5 by hypoxia or by pre-incubation with inhibitors of mitochondrial oxidative phosphorylation prevented further current reduction by AMPK activators, suggesting that AMPK may act as the primary regulator of K v 1.5 downstream of inhibition of mitochondrial oxidative phosphorylation during hypoxia. This conclusion is also supported by previous findings that hypoxia activates AMPK (Evans et al. 2005) and achieves maximal AMPK phosphorylation within ß10 min (Ibe et al. 2013 ).
Crucially, given the possible off-target effects of any pharmacological agents, intracellular dialysis of active and phosphatase-resistant (thiophosphorylated) recombinant AMPK heterotrimers selectively inhibited K v currents in .5 min after extracellular application of (a) 100 μM A769662 or 5 min following intracellular dialysis of the active AMPK heterotrimer (b) (α2β2γ 1, thiophosphorylated, 2 U ml −1 ). B, time course for reduction of whole-cell K + currents during extracellular application of DMSO (1:1000, vehicle control), 100 μM A769662, the combined application of 40 μM compound C and 100 μM A769662; or C, intracellular dialysis of active α2β2γ 1 (thiophosphorylated, 2 U ml −1 ), active α1β1γ 1(thiophosphorylated, 2 U ml −1 ) or inactive α2β2γ 1 (D157A mutant). D, bar chart showing mean ± SEM residual current at the end of each experimental intervention (3.5-5 min). Results are means ± SEM, n = 3-7. * P < 0.05 and * * P < 0.01 vs. control. E, Coomassie blue stained SDS-PAGE (a) and autorad (b) of K v 1.5 protein incubated with okodaic acid, 200 μM AMP, 32 P-ATP in the presence (L1) or absence (L2) of bacterial activated AMPK (α2β2γ 1), and (L3) 1 μg of BSA treated as in L1.
pulmonary arterial myocytes, while a kinase-dead AMPK mutant was without effect. Although our results with C13 and A769662 suggest that an endogenous α1β1-containing complex may regulate K v 1.5 in pulmonary arterial myocytes, our results with intracellular dialysis of α1β1γ1 and α2β2γ1 heterotrimers suggest that both are capable of regulating K v 1.5. It is also interesting to note that AMPK activation not only induced a leftward shift in half maximal activation of K v currents, as previously reported for effects of mitochondrial inhibitors (Firth et al. 2008 ), but also a leftward shift in half maximal inactivation and thus reduced the available non-inactivating current, i.e. the window current. The overall effect would be to lower the threshold for K v 1.5 activation and thus increase the threshold for membrane depolarization, while reducing the opposition to membrane depolarization once initiated. These outcomes argue against a role for K v 1.5 inhibition in the initiation, through membrane depolarisation, of acute HPV. This view is supported by the fact that compound C inhibits K v 1.5, but has little or no effect on resting pulmonary arterial tone despite the fact that it inhibits acute HPV in a concentration-dependent manner (Robertson et al. 2008) . When considered together, our study therefore provides further support for the view that acute HPV is induced in a manner independent of K v 1.5 inhibition (Dipp et al. 2001; Prieto-Lloret et al. 2015) . That aside, our findings suggest that care must be taken when assessing studies that have employed compound C to examine the role of AMPK in pulmonary vascular function, given that the marked attenuation of K v 1.5 by compound C presents an important confounding variable with respect to investigations on myocyte proliferation and the progression of pulmonary hypertension (Ibe et al. 2013) . Moreover in a screen of 70 protein kinases, at least 10 were inhibited by compound C more potently than AMPK (Bain et al. 2007 ). Compound C cannot, therefore, be considered to be a selective inhibitor of AMPK, a point reinforced by our findings.
Our conclusions from studies on native K v currents in pulmonary arterial myocytes were confirmed by further investigations on the regulation of hK v 1.5 stably expressed in HEK 293 cells. Native rat liver AMPK and two combinations (α1β1γ1 and α2β2γ1) of bacterially expressed human AMPK isoforms were found to incorporate near-stoichiometric amounts of phosphate into immunoprecipitated hK v 1.5 channels, and with rat liver AMPK this was stimulated by AMP, making it very unlikely that the phosphorylation was catalysed by a contaminating kinase. AMPK activators and recombinant heterotrimers also inhibited currents carried by recombinant K v 1.5 channels in intact HEK 293 cells. This suggests that AMPK may directly regulate the channel protein even though K v β1, K v β2 and K v β3 may be expressed to varying degrees in HEK 293 cells that stably express K v 1.5 (Fig. 9) , as has been reported previously .
Our results support a model in which inhibition of mitochondrial oxidative phosphorylation by hypoxia in pulmonary arterial myocytes triggers AMPK-dependent inhibition of K v 1.5 channels, in line with the observation that co-expression of K v 1.5 and AMPK reduced K v current and K v 1.5 channel abundance in the cell membrane of oocytes (Mia et al. 2012) . Our finding that AMPK phosphorylates and inhibits K v 1.5 is also entirely consistent with previous evidence that AMPK mediates acute HPV (Evans et al. 2005; Robertson et al. 2008) , and the proposal that AMPK may also contribute to smooth muscle proliferation and the development of pulmonary arterial hypertension (Ibe et al. 2013; Goncharov et al. 2014) . This is evident from the fact that down-regulation of K v 1.5 expression and activity is a hallmark not only of HPV but also of pulmonary hypertension (Yuan et al. 1998; Michelakis et al. 2002; Bonnet et al. 2006; Remillard et al. 2007; Burg et al. 2010; Morales-Cano et al. 2014) . This down-regulation may lead to increased survival of smooth muscle cells due to attenuation of K + channel-dependent apoptosis Brevnova et al. 2004; Moudgil et al. 2006) , and facilitate the phenotypic switch from a contractile to a proliferative state (Cidad et al. 2012 (Cidad et al. , 2015 . Further support for this view may be taken from the finding that over-expression of K v 1.5 enhances apoptosis (Brevnova et al. 2004) , while adenoviral transgene expression of K v 1.5 in vivo reduces pulmonary hypertension and restores HPV (Pozeg et al. 2003) . Therefore, it is possible that dysfunction of the mitochondrial-AMPK signalling pathway may predispose individuals to hypoxia and other forms of pulmonary arterial hypertension (Bonnet et al. 2006) . In this respect, it is interesting to note that single nucleotide polymorphisms (SNPs) in the gene encoding K v 1.5 predispose to pulmonary hypertension and reduce K v 1.5 channel availability in pulmonary arterial myocytes (Remillard et al. 2007) , raising the intriguing possibility that this may be due, at least in part, to alterations in AMPK-dependent regulation of K v 1.5. AMPK phosphorylates target proteins containing a (X,β)XXS/TXXX ( , hydrophobic; β, basic) recognition motif . The protein sequence for K v 1.5 presents 15 serines and 4 threonines susceptible to phosphorylation by serine-threonine kinases (Blom et al. 1999) . However, none of these represents good matches to the consensus recognition sites for AMPK (http://scansite3.mit.edu), despite the fact that our studies on 32 P phosphorylation indicate that the immunoprecipitated channel protein might be a direct substrate for AMPK. This raises two distinct possibilities, (1) AMPK recognises non-canonical sites within the K v 1.5 sequence, as has been shown for other proteins (Jones et al. 2005; Chang et al. 2009; Egan et al. 2011) ; or (2) AMPK phosphorylates one or more associated protein(s), such as the regulatory β subunits. The fact that AMPK phosphorylates and regulates K v 1.5 suggests that its effects are mediated, at least in part, independently of such interactions. Nevertheless, we cannot rule out the possibility that outcomes may be modulated by the β subunits, given that rat pulmonary arterial myocytes express K v β1, K v β2 and K v β3 (Platoshyn et al. 2006 ) and phosphorylation of either K v 1.5 or regulatory K v β subunits may modulate not only channel gating and inactivation kinetics (Holmes et al. 1996; Williams et al. 2002) but also the sensitivity of K v 1.5 to regulation by K v β subunits David et al. 2012; Macias et al. 2014) . It is equally plausible that AMPK-dependent phosphorylation of K v 1.5 in pulmonary arterial myocytes may alter K v α−K v β interactions, sensitivity to metabolic stress, channel trafficking (Martens et al. 1999; Tipparaju et al. 2012) and/or degradation via ubiquitin ligases (Mia et al. 2012; Andersen et al. 2015) . Further studies will be aimed at identifying the AMPK phosphorylation sites on K v 1.5 and on associated β subunits.
In conclusion, we propose that AMPK couples the inhibition of mitochondrial oxidative phosphorylation to K v 1.5 channel inhibition in pulmonary arterial myocytes, which may contribute to the regulation by AMPK of smooth muscle proliferation and thus to the development of pulmonary hypertension. In addition, AMPK-dependent modulation of K v 1.5 channel availability may also contribute to proliferative potential associated with other diseases, such as cancer (Bonnet et al. 2007; Comes et al. 2013; Vallejo-Gracia et al. 2013) .
